Aspect Biosystems receives $200 million government investment

Canadian biotech Aspect Biosystems, which is pioneering the development of bioprinted tissue therapeutics, has received a $72.75 million investment from the Governments of Canada and British Columbia.

Aspect says the investment will support a $200 million, multi-year project to advance its unique clinical biomanufacturing capabilities, full-stack tissue therapeutic platform, and pipeline of bioprinted tissue therapeutics. These next generation therapeutics are designed to replace, repair, or supplement biological functions in the body with the aim of delivering a new class of truly disease-modifying treatments and functional cures for some of the most elusive diseases.

This project will leverage Aspect’s landmark partnership with global healthcare leader Novo Nordisk in diabetes and obesity as well as accelerate Aspect’s own internal therapeutic pipeline for other serious metabolic and endocrine diseases, including liver disease.